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INTRODUCTION
Previous studies indicated that proinflammatory cytokines
such as interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-
and their receptors are increased in patients with both decom-
pensated heart failure (New York Heart Association (NYHA)
functional class III and IV as well as compensated (NYHA
functional class II) (1-3). Furthermore, proinflammatory cyto-
kines have been attributed as contributors to the syndrome of
congestive heart failure and the underlying cardiomyopathic
process of adverse left ventricular remodeling and thus, evolv-
ing into progressive left ventricular dysfunction (4-6).
The origin of proinflammatory cytokines in patients with
heart failure remains unclear, hence the implication of such
proinflammatory cytokines in the pathogenesis of heart fail-
ure is still controversial, which was reflected by the failure
of multicenter clinical trials that used “targeted” approaches
to neutralize TNF- in patients with moderate to advanced
heart failure (7).
Some authors suggested endotoxin may induce cytokine
activation via intestinal bacterial translocation (8). However,
this hypothesis failed to explain elevated cytokines in patients
with compensated heart failure (9). Other studies proposed
myocardium itself produce cytokines due to elevated left ven-
tricular diastolic wall stress (10). Tissue hypoxia and free radi-
cal production was also hypothesized to cause NF- B medi-
ated cytokine production especially from skeletal muscles (11).
In order to determine the cellular source of circulating
proinflammatory cytokines and their soluble receptors, we
measured the proinflammatory cytokine concentrations in
systemic artery, infra-renal inferior vena cava, and coronary
sinus and their concentrations were compared with one anoth-
er to determine the origin of its production. Furthermore,
we correlated the proinflammatory cytokine levels with the
clinical variables and hemodynamic parameters assessed both
at admission and at recovery status. 
MATERIALS AND METHODS
Study Subjects
We consecutively enrolled 30 patients who were admitted
to Ajou University Hospital for congestive heart failure due
to idiopathic dilated cardiomyopathy with various function-
al classes. At admission, we assessed NYHA functional classes,
performed routine clinical evaluations and measured echocar-
diographic parameters. All patients were treated with stan-
dard medical therapy depending upon the severity of heart
failure. After patients achieved hemodynamic stabilization,
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The Origin of Proinflammatory Cytokines in Patients with Idiopathic
Dilated Cardiomyopathy
Proinflammatory cytokines and their receptors are increased in the peripheral blood
of patients with heart failure. We measured cytokines and their receptors in sys-
temic artery (SA), coronary sinus (CS) and infra-renal inferior vena cava (IVC), in
order to investigate their origin and influential factors. Thirty patients with idiopathic
dilated cardiomyopathy were performed echocardiography at admission, and right
heart catheterization after stabilization. Blood was drawn from 3 sites for measure-
ment of tumor necrosis factor- (TNF- ), interleukin-6 (IL-6) and soluble tumor
necrosis factor- receptor (sTNFR) I, II. TNF- at CS (3.25±0.34 pg/mL) was
higher than those of SA (1.81±0.39 pg/mL) and IVC (1.88±0.38 pg/mL, p<0.05).
IL-6 at CS (18.3±3.8 pg/mL) was higher than that of SA (5.8±1.2 pg/mL, p<0.01).
The levels of sTNFR I, II showed increasing tendency in sequence of SA, IVC and
CS. TNF- and sTNFR I, II from all sites were proportional to worsening of func-
tional classes at admission (p<0.05). E/Ea by Doppler study at admission, which
reflects left ventricular end-diastolic pressure (LVEDP) was positively correlated
with TNF- from SA (R=0.71, p<0.01), CS (R=0.52, p<0.05) and IVC (R=0.46,
p<0.05). Thus, elevated LVEDP during decompensation might cause cytokine
release from myocardium in patients with idiopathic dilated cardiomyopathy.
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cardiac catheterization was performed for blood sampling at
femoral artery as a systemic artery, infra-renal inferior vena
cava representative of cytokine production from skeletal mus-
cle and coronary sinus from myocardium, and measurement
of hemodynamic variables including pulmonary capillary
wedge pressure, mean pulmonary arterial pressure, mean
arterial pressure and cardiac index.
Patients with the following criteria were excluded; (1) any
identifiable cause of dilated cardiomyopathy such as history
of heavy alcohol abuse, severe hypertension, primary valvu-
lar disease or history of ischemic heart disease, (2) elevated
cardiac enzyme or EKG change compatible to myocarditis,
(3) history of infectious disease within recent 4 weeks or ele-
vated acute phase reactants (e.g. ESR, C-Reactive protein),
(4) contraindication for cardiac catheterization
We also selected 11 age- and gender-matched control sub-
jects (aged 38 to 60, mean 49 yr, male: 7) who visited Ajou
University Hospital for electrophysiologic study. All the
control subjects had normal coronary angiogram.
All participants gave written informed consents before
entering the study and the study protocol was reviewed by
the ethical committee of Ajou University Hospital.
Blood Sampling
After proper medical therapy, right heart catheterization
and coronary angiography were performed. Under fluoro-
scopic guidance, 7Fr NIH catheter was positioned in the
coronary sinus via subclavian vein. Correct catheter position
was confirmed with contrast injection and oxygen satura-
tion. Pulmonary capillary wedge pressure, mean pulmonary
arterial pressure, mean arterial pressure and cardiac index
were measured during blood sampling.
Cytokine Assay
Blood samples were immediately centrifuged with 5,000
rpmfor 15 min at 4℃. Then, serum was separated into aliquots
and stored at -70℃for a period not exceeding 6 months. Cir-
culating levels of cytokines and their receptors were measured
using commercially available ELISA kits (Quantikine, R &
D systems, Minneapolis, MN, U.S.A.). The intra-assay coef-
ficients of variation were as follows; TNF- (6.0%), sTNFR
I (4.7%), sTNFR II (2.4%) and IL-6 (3.5%).
Statistical Analysis
Statistical analysis was performed with SPSS 8.0 statisti-
cal software (SPSS, Inc. Illinois, U.S.A.). All data are pre-
sented as mean±SEM. Student’s t-test was used for differ-
ences in continuous variables and  2 test was used for cate-
gorical variables. The differences in cytokine levels by NYHA
functional classes were verified using ANOVA. Correlations
of cytokine levels with demographic characteristics were
measured by Pearson’s analysis. p<0.05 was considered sta-
tistically significant.
RESULTS
Characteristics of Study Subjects
Among 30 patients enrolled, 21 were male and 9 were
female, with age ranging from 32 to 67 yr (51.3±9.3 yr).
Mean left ventricular ejection fraction was 27.7±9.5%. Mean
duration of symptoms was 18.5±1.8 days before admis-
sion (Table 1). Seven patients were classified as NYHA func-
tional class I, 8 as II, 6 as III, and 9 as IV at admission (Table
1). At the time of cardiac catheterization after appropriate
medical therapy, all patients with heart failure were com-
pensated and their functional classes had improved (Table 2).
Circulating Levels of Cytokines according to Site of
Origin
Mean values of all the cytokines were at least fivefold high-
er in the patient group than those in the control group from
all the three sampling sites (Fig. 1). We could not measure
TNF- from systemic artery in 9 patients and from inferior
Data are expressed mean±SD. MAP, mean arterial pressure; MPAP,
mean pulmonary arterial pressure; NYHA, New York Heart Association;
PCWP, pulmonary capillary wedge pressure.
Duration from enrollment (days) 4.8±0.5
NYHA Functional class I 11 (37%)
II 19 (63%)
PCWP (mmHg) 13.6±1.8
MAP (mmHg) 92.6±11.2
MPAP (mmHg) 23.4±4.6
Cardiac Index (L/min/m
2) 2.2±0.1
Table 2. Patient characteristics at cardiac catheterization
Data are expressed mean±SD. LV, left ventricle; NYHA, New York Heart
Association.
Gender (M/F) 21/9
Age (yr) 51.3±9.3
NYHA Functional class I 7 (23%)
II 8 (27%)
III 6 (20%)
IV 9 (30%)
Smokers 15  (50%)
Diabetes mellitus 12 (43%)
Hypertension 11 (39%)
Symptom duration (days) 18.5±1.8
Hematocrit (%) 38±4.8
LV Ejection fraction (%) 27.7±9.5
LV End-diastolic Dimension (mm) 65.7±8.7
E/Ea 24.4±6.5
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vena cava in 8 patients, due to limited minimal detection
level. In contrast, TNF- at coronary sinus was measurable
in all patients.
TNF- of 3.25±0.34 pg/mL at coronary sinus was high-
er than that at inferior vena cava (1.88±0.38 pg/mL, p<0.05)
and systemic artery (1.81±0.39 pg/mL) (Fig. 1). The levels
of sTNFR I and II had a tendency to increase in order of
systemic artery, inferior vena cava and coronary sinus with-
out statistical significance, i.e., sTNFR I in systemic artery,
2,088±212 pg/mL; inferior vena cava, 2,125±216 pg/mL;
coronary sinus, 2,368±220 pg/mL (p=NS) and sTNFR II
in systemic artery, 2,880±306 pg/mL; inferior vena cava,
2,945±301 pg/mL; coronary sinus, 3,242±316 pg/mL
(p=NS) (Fig. 1). However, the levels of IL-6 increased sig-
nificantly in the same order (systemic artery, 5.78±1.23
pg/mL; inferior vena cava, 12.1±2.7 pg/mL; coronary sinus,
18.3±3.84 pg/mL, p<0.01) (Fig. 1). Significant differences
were detected in the levels of IL-6 between coronary sinus
and systemic artery (p<0.01), but not between coronary sinus
and inferior vena cava (Fig. 1).
Significant correlations were noted between TNF- from
coronary sinus, and IL-6 from coronary sinus (R=0.44, p<0.05)
and inferior vena cava (R=0.51, p<0.01).
Circulating Levels of Cytokines and Clinical, Hemo-
dynamic Variables
TNF- , sTNFR I and II from inferior vena cava increased
in relation to worsening NYHA functional classes at admis-
sion (R=0.59, 0.64 and 0.52, respectively; p<0.01). The con-
centrations of IL-6 showed a tendency to increase in accor-
dance with worsening functional status without statistical
significance (R=0.32, p=0.06).
Early diastolic mitral inflow versus mitral annular velocity
ratio (E/Ea) at admission by Doppler study, which reflects
left ventricular end diastolic pressure, was positively corre-
lated with TNF- from systemic artery (R=0.71, p<0.01),
coronary sinus (R=0.52, p<0.05) and inferior vena cava (R=
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Fig. 1. Levels of proinflammatory cytokines at different sites. Data are expressed mean±SEM. *: p<0.05 compared with TNF- from IVC,
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0.46, p<0.05) (Fig. 2). In contrast, pulmonary capillary wedge
pressure measured during right catheterization did not show
any significant correlation with cytokines.
DISCUSSION
Since Levine et al. first reported that, among patients with
congestive heart failure, circulating levels of TNF- are most
markedly increased in those with the most advanced disease
and cachexia (13), many other studies have observed that
cytokines are sufficient to mimic some aspects of the so-called
heart failure phenotype, including progressive left ventricu-
lar dysfunction, pulmonary edema, left ventricular remodel-
ing, fetal gene expression and cardiomyopathy (4-6). Thus,
the “cytokine hypothesis” holds that heart failure progresses,
at least in part, as a result of the toxic effects exerted by endoge-
nous cytokine cascades on the heart and the peripheral cir-
culation (14). However, the site of cytokine production in
patients with congestive heart failure is still poorly understood.
Anker et al. proposed that elevated plasma cytokines in heart
failure resulted from a cascade of events consisting of mesen-
teric venous congestion, bowel wall edema, and intestinal
bacterial translocation (8). But elevations in plasma cytokines
have been observed in patients with functional class II and
even in many patients without peripheral edema (9). Other
studies proposed elevated left ventricular diastolic wall stress
stimulates myocardium to produce cyto-kines (10). Tissue
hypoxia and free radical production due to impaired vasodila-
tor reserve was also hypothesized to cause NF- B mediated
cytokine production especially from skeletal muscles. 
Deliargyris et al. suggested that elevated IL-6 in patients
with heart failure is the result of extracardiac production (15).
In contrast, Petretta et al. found no significant differences in
the levels of cytokines among coronary sinus, ascending aorta,
inferior vena cava and hepatic vein (16). However, there is
substantial limitation in their results because their subjects
had various causes of heart failure including ischemic heart
disease. Our study may be more relevant, for all the cases in
the study were diagnosed as idiopathic dilated cardiomyo-
pathy with various functional classes, and left ventricular end-
diastolic pressure was measured twice; first, at admission,
indirectly by Doppler study and after proper medical therapy,
second, at recovery status, by cardiac catheterization.
The TNF- molecule (a 157-amino acid polypeptide) exists
bioactive as a membrane-bound and secreted molecule (17).
The activated macrophage is the main source of TNF- ,
although other cells releasing TNF- include lymphocytes,
fibroblasts, neutrophils, smooth muscle cells and mast cells
(18). Furthermore, adult mammalian myocardial cells can
produce TNF- with extracellular stimuli such as endotox-
in, hypoxia or increased mechanical stress (10).
Our data with the highest concentration of TNF- at coro-
nary sinus seem to support the concept of the myocardial cyto-
kine production. Torre-Amione et al. demonstrated myocar-
dial expression of TNF- in failing human hearts (19). Myocar-
dial stretch was a sufficient stimulus for the induction of
TNF- and mRNA biosynthesis in feline myocardium (10).
Nagueh et al. investigated E/Ea by Doppler study provides
the best index for the prediction of pulmonary capillary
wedge pressure, irrespective of the diastolic filling pattern
(12). Significant correlation between TNF- and baseline
E/Ea was observed in the present study (Fig. 2). However,
after compensation with appropriate medical therapy, no
significant correlation was noted between TNF- and pul-
monary capillary wedge pressure gained at cardiac catheteri-
zation. Consequently, we deduced stretched myocardium
may be the stimulus of increased level of TNF- .
TNF- also orchestrates the inflammatory cascade through
regulation of transduction for proinflammatory cytokines
such as IL-1 and IL-6, and nitric oxide synthase (20), which
was reflected as a significant correlation between TNF-
and IL-6 in the present study.
TNF- acts at the cellular level via both type I (p55) and
type II (p75) receptors and recently, it has been suggested
that both of them are present in the human myocardium.
The extracellular domain fragments of both TNF receptors
shed from cell surfaces can be detected as soluble forms in the
blood and urine (21). At physiologic concentrations, sTN-
FRs may act as ‘slow-release reservoir’ of bioactive TNF- ,
but at higher concentrations, as in patients with severe heart
failure, they could inhibit the pathological increase of TNF-
activity (19).
Saraste et al. reported sTNFR II identified a subgroup of
heart failure patients with increased cardiomyocyte apopto-
sis (22). Finally, the increased levels of sTNFR II were sig-
nificantly correlated with poor short-term prognosis of heart
failure patients (23).
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Fig. 2. Correlation between TNF- at coronary sinus and E/Ea by
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Although our study failed to demonstrate any significant
difference in the levels of sTNFR I and II from the different
sites of sampling, the absence of a transmyocardial gradient
of cytokines does not rule out myocardial production of
cytokines due to the diffusion barrier between interstitial
space and coronary venous effluent and relatively high molec-
ular weight compared with TNF- and IL-6 (24).
Serum IL-6 was known as the most powerful independent
predictor of heart failure episodes and mortality or need for
heart transplantation during heart failure management (25).
Tsutamoto et al. implicated IL-6 is produced mainly in
the periphery in heart failure patients (26), but their study
population is different from ours in background; 60% of
subject patients had history of myocardiac infarction. In the
setting of ischemic heart failure, both myocardial necrosis
and successful reperfusion, and peripheral vascular tissue
may affect to increase myocardial IL-6 production (26, 27).
The mechanism for elaboration of IL-6 in idiopathic dilated
cardiomyopathy has not been elucidated. TNF- may be
sufficient to induce IL-6 gene and protein expression in a
variety of cell types, suggesting that there may be a ‘cytokine
cascade’ in the setting of heart failure (28). We also identi-
fied a significant positive correlation between the levels of
TNF- and IL-6, which is similar to other study (29). On
the basis of our results, we suggested that IL-6 might be
produced mainly in the myocardium. But it remains con-
troversial to determine whether the local myocardial pro-
duction of IL-6 is secondary to increased TNF- , or directly
related to the myocardial tissue or some combination of both.
In our study, we conclude that myocardium might be the
major source of proinflammatory cytokines in idiopathic
dilated cardiomyopathy. It might be relevant in determin-
ing the origin for all the subjects had non-ischemic heart
failure with various functional status.
Accordingly, we presumed that increased myocardial wall
stress might lead to sustained expression of stretch-derived
genes and increased oxidative stress as a result of subendo-
cardial hypoperfusion, with resultant activation of families
of genes which might be translated in subsequent produc-
tion of cytokines.
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